Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

nformation identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedSeptember 30,Nine Months Ended September 30,(In thousands, except per share data)2010200920102009(unaudited)(unaudited)Revenues:Collaborative research$  632$  1,650$  3,437$  8,042Subscription and license fees1494812181,246Total revenues7812,1313,6559,288Operating expenses:Research and development, including stock-based compensation

of $751, $733, $2,366 and $2,328, respectively20,08619,32061,41362,404General and administrative, including stock-based compensation

of $582, $547, $1,592 and $1,750, respectively4,9484,56815,53514,993Total operating expenses25,03423,88876,94877,397Loss from operations(24,253)(21,757)(73,293)(68,109)Gain on investments, net-1851411,008Interest income51103468669Interest expense(637)(785)(2,093)(2,180)Other expense, net(2,700)(516)(4,025)(2,037)Consolidated loss before taxes(27,539)(22,770)(78,802)(70,649)Income tax benefit2610226102Consolidated net loss(27,513)(22,668)(78,776)(70,547)Less: Net loss attributable to noncontrolling interest in Symphony Icon, Inc.-3,526-9,772Net loss attributable to Lexicon Pharmaceuticals, Inc.$  (27,513)$  (19,142)$  (78,776)$  (60,775)Net loss  attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted$   (0.08)$  (0.14)$  (0.27)$  (0.44)Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc.  per common share, basic and diluted337,404137,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The DNA Microarray market market was valued at ... grow at a CAGR of 15.2% from 2014 ... the DNA Microarray for an in-depth analysis of ... various tables and figures. , http://www.micromarketmonitor.com/market-report/dna-microarray-reports-5177428198.html ... instrument, consumables, and services, where the consumables market ...
(Date:12/13/2014)... New York (PRWEB) December 13, 2014 ... its global network and Cold Chain capabilities, and is ... Tower in Paris, France, to serve Life Science clients ... facility equipped with a controlled-ambient warehouse, will provide 24/7 ... for vaccines and investigational drugs, patient-clinical specimens, API, following ...
(Date:12/13/2014)... N.J. and SAN ANTONIO ... LLC (Janssen) today announced the presentation of data at ... Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus best ... anemia in patients with metastatic breast cancer receiving standard ... objective, which was to rule out a 15 percent ...
(Date:12/12/2014)... December 11, 2014 Electronic Data ... for claims management and supply chain management to ... of transactions. The benefits associated with the use ... time of transactions has helped improve the acceptance ... Browse 70 market data tables and 107 figures ...
Breaking Biology Technology:DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... that a new market research report is available in its ... and companies http://www.reportlinker.com/p0203543/Gene-Therapy---technologies-markets-and-companies.html ... on gene therapy with 72 tables and 13 figures ... 700 selected references from the literature - Estimates ...
... Dec. 21, 2010 Exagen Diagnostics, Inc., a specialty ... today announced that it has been awarded $400,000 in ... program, which was created by Congress as part of ...  Proceeds from the grants will be used to advance ...
... Mass. and BRANFORD, Conn., Dec. 20, 2010 ... oncology-focused molecular diagnostics company, and HistoRx, Inc., ... to advance individualized patient care, today announced ... Metamark a worldwide license to the AQUA ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program 2Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... see the flowers of Edinburgh in full bloom in the depths ... the impact of global warming on spring flowering, published today in ... dating back to the late nineteenth century, has been used to ... further warming will have on plant life by the year 2080. ...
... faster than in any other location on Earth. Researchers at ... indicating that the changes are astonishingly fast. Many original species ... species from southern areas to migrate north, where they occupy ... renowned Science magazine will publish a joint article ...
... ANN ARBOR, Mich.---The growth of cancerous tumors is ... free radicals---highly reactive oxygen-containing molecules. It stands to ... antioxidants, which inhibit the rogue radicals, or with pro-oxidants, ... cancer cells to the point of vanquishing them. ...
Cached Biology News:Early spring time for Edinburgh? Study predicts effect of global warming on spring flowers 2The change in Arctic nature foreshadows the global environment of the future 2New method monitors early sign of oxidative stress in cancer 2
... to Dideoxycytidine Dideoxycytidine is a cytidine analog ... inhibiting retroviral activity. Immunogen: Chemical ... Specificity: The specificity of the ddC antiserum ... moles of ddC to moles of ddC analog ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
... features, the 1400 Series will maximize your comfort level ... every time you use it. , Energy ... by as much as 50% from competitive models, saving ... cabinet. Multiply this savings by the number of ...
... with circular clear acrylic chamber for complete ... Oven features microprocessor operation for precise mixing ... unit., Carousel rotates at 11 rpm; ... removable , Bottle Capacity - four ...
Biology Products: